Eflornithine hydrochloride hydrate
Based on 23 publication(s) in Google Scholar
Eflornithine hydrochloride hydrate (DFMO hydrochloride hydrate) is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase. Eflornithine hydrochloride hydrate is a medication for the treatment of African trypanosomiasis and excessive facial hair growth in women.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 96020-91-6
- Formula: C6H15ClF2N2O3
- Molecular Weight:236.64
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
HY-124617A
AMXT-1501 tetrahydrochloride
-
HY-B1776
Spermidine
-
HY-18739
Phorbol 12-myristate 13-acetate
-
HY-13746B
Sardomozide dihydrochloride
-
HY-12248
Telaglenastat
-
HY-B0404A
Benserazide hydrochloride
-
HY-B0744BR
Eflornithine hydrochloride hydrate (Standard)
-
HY-66019
FITC
-
HY-13610A
N1,N11-Diethylnorspermine tetrahydrochloride
-
HY-13259
MG-132
-
HY-10256
Adezmapimod
-
HY-12028
PD98059
Publications Citing Use of MedChemExpress (MCE) Eflornithine hydrochloride hydrate
More- Nature. 2026 Jul;655(8121):240-250. [Abstract]
- Immunity. 2025 Aug 12;58(8):2019-2034.e11. [Abstract]
- Nat Commun. 2025 Dec 8. [Abstract]
- Nat Commun. 2024 Mar 19;15(1):2461. [Abstract]
- J Clin Invest. 2026 Jun 11.
- Adv Sci (Weinh). 2025 Nov 21:e12508. [Abstract]
- Sci Adv. 2023 May 19;9(20):eade0718. [Abstract]
- Phytomedicine. 2025 Jun:141:156660. [Abstract]
- Clin Cancer Res. 2025 Nov 20. [Abstract]
- JACC Basic Transl Sci. 2022 Aug 3;7(8):820-840. [Abstract]
- Cell Rep. 2025 Feb 28;44(3):115370. [Abstract]
- Cell Rep. 2025 Jan 28;44(1):115123. [Abstract]
- Food Biosci. 2023 Oct, 55, 102970.
- RSC Adv. 2019 Apr 9;9(20):11026-11037. [Abstract]
- Cancer Nanotechnol. 2023 May 9.
- Commun Biol. 2019 May 8:2:171. [Abstract]
- Front Oncol. 2021 Mar 11:11:636373. [Abstract]
- J Cardiovasc Transl Res. 2025 Jun;18(3):459-470. [Abstract]
- Biochem Biophys Res Commun. 2026 Feb 12:800:153251. [Abstract]
- Onco Targets Ther. 2020 Nov 17:13:11697-11709. [Abstract]
- The University of Texas at San Antonio. 2025.
- Preprints. 2025 May 22.
- bioRxiv. 2024 Jan 15.
Customer Validation & Images
-
In Vivo Efficacy Study
-
Flow Cytometry
-
RT-PCR
-
Flow Cytometry
-
Histological Imaging/Staining
All Parasite Isoforms
More
Biological Activity
|
Trypanosoma |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| J774 | IC50 |
>1000 μM
Compound: S3
|
Cytotoxicity against J774.1 cell line after 48 hrs
Cytotoxicity against J774.1 cell line after 48 hrs
|
[PMID: 16516467] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 96020-91-6
-
Appearance Solid
-
Molecular Weight 236.64
-
Formula C6H15ClF2N2O3
-
Color White to off-white
-
SMILES
NC(CCCN)(C(F)F)C(O)=O.[H]Cl.O
-
Synonyms
DFMO hydrochloride hydrate; MDL-71782 hydrochloride hydrate; RMI-71782 hydrochloride hydrate; α-difluoromethylornithine hydrochloride hydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (23)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Jul;655(8121):240-250. PMID: 42236947 -
Immunity
Polyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells. [Abstract]2025 Aug 12;58(8):2019-2034.e11. PMID: 40749666
Eflornithine hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: Immunity. 2025 Aug 12;58(8):2019-2034.e11. [Abstract]
Csnk2bTreg−/− and Csnk2bfl/fl mice were inoculated with B16.F10 cells and then orally administered Eflornithine hydrochloride hydrate (1% w/v) in combination with subcutaneous injection of AMXT 1501 around the tumor. We measured tumor growth and analyzed the phenotype of Treg cells in the tumor microenvironment (TME) using multicolor flow cytometry. The combination therapy had no effect on tumor growth in Csnk2bTreg−/− mice but significantly inhibited tumor growth in Csnk2bfl/fl mice.
-
Nat Commun
2025 Dec 8. PMID: 41361241 -
Nat Commun
Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer. [Abstract]2024 Mar 19;15(1):2461. PMID: 38504107 -
-
Adv Sci (Weinh)
Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer. [Abstract]2025 Nov 21:e12508. PMID: 41271556
Eflornithine hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 21:e12508. [Abstract]
Bar graphs showing the proportion of ALDH+ cells in OVCAR3, OVCAR8, and SKOV3 treated with THP-1-derived Mφ+ACs CM, THP-1-derived Mφ+ACs treated with 1 mM Eflornithine CM, respectively, for 48 h were presented.
Eflornithine hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 21:e12508. [Abstract]
Bar graph showing the relative mRNA expression of SOX2, ALDH1A1, and ALDH1A3 in OVCAR3 treated with THP-1 derived Mφ +ACs CM, THP-1 derived Mφ+ACs treated with 1 mM Eflornithine CM separately for 48 h.
-
Sci Adv
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8+ T cell cytotoxicity and proliferation. [Abstract]2023 May 19;9(20):eade0718. PMID: 37205755
Eflornithine hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 May 19;9(20):eade0718. [Abstract]
Percentage of IFN-γ+ and mean fluorescence intensity (MFI) of Ki-67 in CD8+ T cells after anti-CD3 antibody stimulation versus anti-CD3 antibody plus rSema4A stimulation with or without Sardomozide Dihydrochloride (10 μM) and Eflornithine hydrochloride hydrate (500 μM).
-
Phytomedicine
Oleic acid regulates CD4+ T cells differentiation by targeting ODC1-mediated STAT5A phosphorylation in Vogt-Koyanagi-Harada disease. [Abstract]2025 Jun:141:156660. PMID: 40203473 -
Clin Cancer Res
Spermidine Secreted by Apoptotic Cells Enhances Chemotherapy Resistance by Modulating β-Catenin Activity in Osteosarcoma. [Abstract]2025 Nov 20. PMID: 41263700 -
JACC Basic Transl Sci
Targeting Myocardial Mitochondria-STING-Polyamine Axis Prevents Cardiac Hypertrophy in Chronic Kidney Disease. [Abstract]2022 Aug 3;7(8):820-840. PMID: 36061341 -
Cell Rep
Intestinal microbiota affects the progression of colorectal cancer by participating in the host intestinal arginine catabolism. [Abstract]2025 Feb 28;44(3):115370. PMID: 40022728 -
Cell Rep
2025 Jan 28;44(1):115123. PMID: 39932195 -
-
RSC Adv
Spermine modified polymeric micelles with pH-sensitive drug release for targeted and enhanced antitumor therapy. [Abstract]2019 Apr 9;9(20):11026-11037. PMID: 35520220 -
-
Commun Biol
2019 May 8:2:171. PMID: 31098404
Eflornithine hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2019 May 8:2:171. [Abstract]
Eflornithine (DFMO) was administered as a 1% solution in drinking distilled H₂O to mice for 14 days. The mean DFMO consumption of mice was ∼1.5 g/kg/d. Immunostaining of IDO1 in the ileum after L-Orn administration in wt mice or after L-Orn inhibitor DFMO administration in human REG3Atg mice was performed.
Eflornithine hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2019 May 8:2:171. [Abstract]
Eflornithine (DFMO) was administered as a 1% solution in drinking distilled H₂O to mice for 14 days. The mean DFMO consumption of mice was ∼1.5 g/kg/d. HPLC/MASS of L-Kyn in the ileum epithelial cells after administration of L-Orn or L-Orn inhibitor DFMO.
Eflornithine hydrochloride hydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2019 May 8:2:171. [Abstract]
Eflornithine (DFMO) was administered as a 1% solution in drinking distilled H₂O to mice for 14 days. The mean DFMO consumption of mice was ∼1.5 g/kg/d. Flow cytometry of RORγt (+) IL-22(+) cells in the ileum of mice after administering L-Orn or L-Orn inhibitor DFMO.
-
Front Oncol
Dual Inhibition of Ornithine Decarboxylase and A1 Adenosine Receptor Efficiently Suppresses Breast Tumor Cells. [Abstract]2021 Mar 11:11:636373. PMID: 33777791 -
J Cardiovasc Transl Res
LACC1 Enhances Polyamine Immunometabolism in Inflammatory Macrophages to Inhibit Atherosclerosis Progression. [Abstract]2025 Jun;18(3):459-470. PMID: 40293654 -
Biochem Biophys Res Commun
Alpha-difluoromethylornithine suppresses angiogenesis via the FLI1-CLEC14A-VEGFC pathway in retinal endothelial cells. [Abstract]2026 Feb 12:800:153251. PMID: 41548484 -
Onco Targets Ther
Simultaneous Inhibition of Ornithine Decarboxylase 1 and Pyruvate Kinase M2 Exerts Synergistic Effects Against Hepatocellular Carcinoma Cells. [Abstract]2020 Nov 17:13:11697-11709. PMID: 33244237 -
-
-
Solvent & Solubility
H2O : 83.33 mg/mL (352.14 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (422.58 mM); Clear solution; Need ultrasonic
Protocol
Mice: The skin area where the hair is removed is then treated with the eflornithine hydrochloride 13.9% cream (-50 mg per mouse per treatment) using a spatula 2 times a day in an interval of at least 8 h for a maximum period of 36 days[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Burri C, et al. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003 Jun;90 Supp 1:S49-52. [Content Brief]
[2]. Balfour JA, et al. Topical eflornithine. Am J Clin Dermatol. 2001;2(3):197-201; discussion 202. [Content Brief]
[3]. Kumar A, et al. A method to improve the efficacy of topical eflornithine hydrochloride cream. Drug Deliv. 2016 Jun;23(5):1495-501. [Content Brief]
[4]. Lipke DW, et al. Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension. Clin Exp Hypertens. 1997 Apr;19(3):297-312. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 4.2258 mL | 21.1291 mL | 42.2583 mL | 105.6457 mL |
| 5 mM | 0.8452 mL | 4.2258 mL | 8.4517 mL | 21.1291 mL | |
| 10 mM | 0.4226 mL | 2.1129 mL | 4.2258 mL | 10.5646 mL | |
| 15 mM | 0.2817 mL | 1.4086 mL | 2.8172 mL | 7.0430 mL | |
| 20 mM | 0.2113 mL | 1.0565 mL | 2.1129 mL | 5.2823 mL | |
| 25 mM | 0.1690 mL | 0.8452 mL | 1.6903 mL | 4.2258 mL | |
| 30 mM | 0.1409 mL | 0.7043 mL | 1.4086 mL | 3.5215 mL | |
| 40 mM | 0.1056 mL | 0.5282 mL | 1.0565 mL | 2.6411 mL | |
| 50 mM | 0.0845 mL | 0.4226 mL | 0.8452 mL | 2.1129 mL | |
| 60 mM | 0.0704 mL | 0.3522 mL | 0.7043 mL | 1.7608 mL | |
| 80 mM | 0.0528 mL | 0.2641 mL | 0.5282 mL | 1.3206 mL | |
| 100 mM | 0.0423 mL | 0.2113 mL | 0.4226 mL | 1.0565 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Eflornithine hydrochloride hydrate Related Classifications
HY-B0744B Related Classifications
Powered by Bioz